PDGFR in myeloid/lymphoid neoplasms with eosinophilia and TK fusions

2 EU-approved indications in myeloid/lymphoid neoplasms with eosinophilia and TK fusions need a PDGFR result: imatinib (any line) and imatinib (advanced).

Line of therapy

Approved indications, Myeloid/lymphoid neoplasms with eosinophilia and TK fusions
DrugBiomarker requirementRegimenSettingConditions
FIP1L1::PDGFRA fusion1
Imatinib
Glivec
FIP1L1-PDGFRalpha rearrangement
Monotherapy
Any line
advanced
None
PDGFR fusion1
Imatinib
Glivec
Monotherapy
Any line
None

See also

Label wording2

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Imatinib (Glivec)
    adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
  2. Imatinib (Glivec)
    adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.